Comparative Pharmacology
Head-to-head clinical analysis: MIDAZOLAM versus NAYZILAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDAZOLAM versus NAYZILAM.
MIDAZOLAM vs NAYZILAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Midazolam is a benzodiazepine that potentiates gamma-aminobutyric acid (GABA) activity by binding to the benzodiazepine site on GABA-A receptors, enhancing GABA's inhibitory effects, leading to increased chloride ion conductance, hyperpolarization, and neuronal inhibition.
Nayzilam (midazolam) is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal activity.
IV: 0.5-2 mg initial, titrate by 0.5-1 mg increments every 2-3 min; typical total 2.5-5 mg. IM: 0.07-0.08 mg/kg (usual 5 mg). Oral: 7.5-15 mg as a single premedication dose.
5 mg intranasally as a single dose; may repeat once after 10 minutes if needed. Maximum 10 mg per episode.
None Documented
None Documented
Clinical Note
moderateMidazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Midazolam is combined with Fluticasone propionate."
Clinical Note
moderateMidazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Midazolam."
Clinical Note
moderateMidazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Midazolam."
Clinical Note
moderateMidazolam + Cyclosporine
Terminal elimination half-life: 1.5-2.5 hours in healthy adults; prolonged in elderly (5-6 hours), obesity, hepatic cirrhosis (up to 20 hours), and critical illness.
Terminal elimination half-life of midazolam is 1.5–2.5 hours, but for NAYZILAM (midazolam nasal spray) the effective half-life for anticonvulsant effect is approximately 2–3 hours due to prolonged absorption; clinical context: used for seizure clusters, duration of effect may persist for 4–6 hours.
Renal: approximately 45-57% as metabolites (primarily 1-hydroxymidazolam glucuronide) and <1% unchanged; fecal: 2-10% via biliary excretion.
Renal excretion as metabolites (primarily glucuronide conjugates) and unchanged drug; approximately 15% recovered in urine as unchanged midazolam, with the remainder as metabolites; <1% excreted in feces via biliary elimination.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Midazolam."